Massive splenomegaly in myeloproliferative disorders treated by splenic artery infusion of cytarabine.
Ten patients with myeloproliferative disorders and massive splenomegaly were treated with splenic artery infusions of cytarabine. Nine patients demonstrated a response to treatment with reduction in spleen size. Three patients had the procedure repeated on subsequent occasions. Relief from pain was the most significant clinical benefit; lasting for up to 6 months regardless of the rate of splenic re-enlargement.
D001772:Blood Cell Count / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D007269:Injections, Intra-Arterial; D009196:Myeloproliferative Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D013157:Splenic Artery; D013163:Splenomegaly / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D003561:Cytarabine